Patheon Reaches Agreement With BSP Pharmaceuticals for Development and Manufacture of Cytotoxics #azur #pharma

Posted On Jul 27 2017 by

#bsp pharma # Patheon Reaches Agreement With BSP Pharmaceuticals for Development and Manufacture of Cytotoxics TORONTO, July 2 /PRNewswire/ — Patheon (TSX:PTI), a global provider of drug development and manufacturing services to the international pharmaceutical industry, has completed a shareholders agreement and a sales and marketing agreement with Italy’s BSP Pharmaceuticals, a company focussed on the development and manufacturing of cytotoxic pharmaceutical products. Under the terms of the sales and marketing agreement, Patheon will promote BSP’s cytotoxic manufacturing capacity and development services. Mr. Aldo Braca, President, Patheon Europe will be President and Chief Executive Officer of BSP Pharmaceuticals. Patheon is …


Pharmaceutical Development Jobs #pharma #drugs

Posted On Jul 27 2017 by

#pharmaceutical research jobs # Pharmaceutical Development Jobs Make a meaningful difference If you’re setting your sights on a career in Pharmaceutical Development, then you’ve already decided that you want to make a difference. There’s no better place to make that happen than at AstraZeneca. Help us find the answers to some of humankind’s biggest health problems. There is a real and urgent need for cutting-edge science and innovative treatment approaches. We’re looking for individuals who can apply their talents and make a difference to patients all over the world. Turning molecules into medicines In Pharmaceutical Development you can use your …


Pharma research and development outsourcing: PwC #pharma #dynamics

Posted On Jul 25 2017 by

#outsourcing pharma # R /* 728×90, создано 05.02.11 */ google_ad_slot = “6127977750”; google_ad_width = 670; google_ad_height = 90; //–>


Welcome to MWB Consulting – Your Pharmaceutical Development Experts #am #pharma

Posted On Jul 25 2017 by

#pharma consulting companies # As pharmaceutical development experts, MWB Consulting can engage with you in all phases of product development, regulatory approval and postmarketing compliance. P A R T N E R S MWB Consulting is the leading professional service company providing international clients with effective solutions for the development and postmarketing support of pharmaceutical products and devices. Our promise is to provide accurate and honest consulting advice allied to knowledge, efficiency and experience applied to the implementation of all our clients� projects. MWB Consulting provides superb drug development consulting services for our key programs. Medical Director, EU biotechnology company …


Raptor Pharma to Stop Development of Liver Drug: Here – s Why: Healthy Living #biggest

Posted On Jul 25 2017 by

#raptor pharma # Raptor Pharma to Stop Development of Liver Drug: Here s Why Raptor Pharma announced that it will no longer pursue the development of its experimental drug RP103 as treatment for the liver disease Nonalcoholic steatohepatitis in children. (Photo. Bill Brooks | Flickr) Raptor Pharmaceutical Corporation is pulling the plug on an experimental drug as treatment for a liver disease. In a statement released on Monday, Sept.14, the biopharmaceutical company said that the drug called RP103 (cysteamine bitartrate) did not meet the main goals in the Phase 2b CyNCh study. The study, which involved 169 participants between 8 …


Outsourced Pharma, Contract Pharmaceutical, CRO, CMO, Pharmaceutical Drug Development Services #global #pharm

Posted On Jul 24 2017 by

#cro pharma # I didn t quite buy into the DCAT announcement regarding its departure from the Waldorf Astoria, the long-time central location for DCAT Week in New York City each spring. Call me cynical a degree in public relations can do that but I just couldn t believe checking out of the Waldorf would be as easy as it sounded. I took this cynicism directly to Margaret Timony, Executive Director of the Drug, Chemical Associated Technologies Association. At the turn of the 21st century, a rare, Houston-based biotech, busy pursuing the development of its own drugs and IP, discovers …


CDRD-Canada – s national drug development – commercialization engine #par #pharma

Posted On Jul 24 2017 by

#drug research companies # On June 3rd, CDRD hosted our global partners including the US National Institutes of Health (NIH), the European Infrastructure for Translational Medicine (EATRIS), Therapeutic Innovation Australia and MRC Technology (UK). On May 26th, CDRD hosted a partnership appreciation lunch and open house. Thank you to everyone for your ongoing support! Quark Venture has made a significant seed investment in Sitka Biopharma – a critical value-creating event that will enable Sitka to advance their lead compound for the treatment of bladder cancer into clinical trials. In total, over one-third of all the life science companies included in …


Research – Development News Channel #pharmaceutical #reps

Posted On Jul 13 2017 by

#latest pharmaceutical news # Research Development News Channel Antibody reduces harmful brain amyloid plaques in Alzheimer’s patients Although the causes of Alzheimer’s disease are still unknown, it is clear that the disease commences with progressive amyloid deposition in the brains of affected persons between ten and fifteen years before the emergence of initial clinical symptoms such as memory loss. Researchers have now been able to show that Aducanumab, a human monoclonal antibody, selectively binds brain amyloid plaques, thus enabling microglial cells to remove the plaques. Last Updated: Saturday, 03 September 2016 Caffeine and its analogues revert memory deficits by normalizing …


Pharmaceutical Research and Development Jobs #bio #pharmaceutical #companies

Posted On Jul 10 2017 by

#pharmaceutical research companies # Pharmaceutical Research and Development Jobs Research and Development is the lifeblood of our business. The epicentre around which everything else revolves. The world population has doubled in the last 50 years from three billion to six billion. By 2050, it s expected to reach nine billion. The medical need is great. But at AstraZeneca, we are there, meeting today s pharmaceutical needs. Exploring solutions. Poised to conquer the challenges of the future. At the heart of our unwavering commitment to breakthrough prescription biopharmaceuticals: Research and Development (R D) Careers. Our 12,000 pharma scientists are united across …


Research – Development News Channel #pharmacy #industry #news

Posted On Jul 6 2017 by

#latest pharmaceutical news # Research Development News Channel Antibody reduces harmful brain amyloid plaques in Alzheimer’s patients Although the causes of Alzheimer’s disease are still unknown, it is clear that the disease commences with progressive amyloid deposition in the brains of affected persons between ten and fifteen years before the emergence of initial clinical symptoms such as memory loss. Researchers have now been able to show that Aducanumab, a human monoclonal antibody, selectively binds brain amyloid plaques, thus enabling microglial cells to remove the plaques. Last Updated: Saturday, 03 September 2016 Caffeine and its analogues revert memory deficits by normalizing …